Regulatory Filing, Business Reorganization, Voluntary Product Recall, Certification, and Research Grant - Research Reports on Mohawk, Johnson Controls, Baxter, Boston Scientific and Thermo Fisher

NEW YORK, September 22, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Mohawk Industries, Inc. (NYSE: MHK), Johnson Controls Inc. (NYSE: JCI), Baxter International Inc. (NYSE: BAX), Boston Scientific Corporation (NYSE: BSX) and Thermo Fisher Scientific, Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6636-100free.

--
Mohawk Industries, Inc. Research Reports
On September 11, 2014, Mohawk Industries, Inc. (Mohawk) filed Form 8-K (Current Report) with the SEC. According to the filing, Mohawk has made certain modifications to its three-year, on-balance-sheet securitization facility on the date of filing. The modifications allow Mohawk to increase the aggregate borrowings available under the securitization facility from $300 million to $500 million as well as decrease the interest margins on certain borrowings. As per the filing, the securitization facility was established on December 19, 2012 and will expire on December 19, 2015, unless terminated earlier or extended subsequently. The full research reports on Mohawk are available to download free of charge at:

http://www.analystsreview.com/Sep-22-2014/MHK/report.pdf

--
Johnson Controls Inc. Research Reports
On September 15, 2014, Johnson Controls Inc. (Johnson Controls) announced reorganization of its Building Efficiency business in order to align it with the Company's long-term strategies, thereby positioning it for profitable global growth. The Company informed that its North America branch business will operate separately from Building Efficiency's global products business, effective immediately. Johnson Controls expects the core heating, ventilation and air conditioning (HVAC) products organization to drive profitable global growth through investments in key HVAC product offerings. The Company's North America branch business will operate in its current form as a direct channel providing HVAC systems, services and solutions. Commenting on the reorganization, Alex Molinaroli, Chairman and CEO stated, "As we continue to evolve as a global multi-industrial company, reorganizing Building Efficiency, along with our ongoing investments and growth initiatives, solidifies our focus and commitment on the business as a core strategic platform for Johnson Controls." The full research reports on Johnson Controls are available to download free of charge at:

http://www.analystsreview.com/Sep-22-2014/JCI/report.pdf

--
Baxter International Inc. Research Reports
On September 16, 2014, Baxter International Inc. (Baxter) announced the voluntary recall of one lot (lot number: P318220) of Potassium Chloride Injection 10mEq per 100mL, product code 2B0826, to the hospital/pharmacy/nurse level due to a labeling error on the shipping cartons in a single lot. The Company stated that the units of Gentamicin Sulfate Injection, 80 mg in 100 mL, product code 2B0862, may be found in the shipping cartons labeled for the above mentioned lot number of Potassium Chloride Injection. Baxter informed that Potassium Chloride is indicated for treatment of potassium deficiency and administered intravenously, while Gentamicin Sulfate is an antibacterial drug for intravenous administration. The affected lot of Potassium Chloride Injection was distributed in the United States between May 26, 2014, and August 8, 2014. The Company added that no adverse events related to this matter have been reported till date. The full research reports on Baxter are available to download free of charge at:

http://www.analystsreview.com/Sep-22-2014/BAX/report.pdf

--
Boston Scientific Corporation Research Reports
On September 17, 2014, Boston Scientific Corporation (Boston Scientific) reported that it has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for treating tremor, including essential tremor (ET) - the most common form of this movement disorder. According to the Company, the Vercise DBS System is the first system that provides precise neural targeting and a rechargeable battery with a life of 25 years. Maulik Nanavaty, President, Neuromodulation, Boston Scientific stated, "With the launch of the Vercise DBS System for the treatment of patients with Parkinson's disease in 2012, for dystonia in 2013, and now for tremor, Boston Scientific continues to demonstrate its commitment to provide more access to DBS therapy to more patients." The full research reports on Boston Scientific are available to download free of charge at:

http://www.analystsreview.com/Sep-22-2014/BSX/report.pdf

--
Thermo Fisher Scientific, Inc. Research Reports
On September 17, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher), together with UC San Diego Office of Research Affairs, announced the annual Duane Roth Innovation Grant, providing a $50,000 funding opportunity to scientific investigators at UC San Diego for sponsored research supporting proof of concept and technology applications studies. The grant recognizes late Duane Roth, the dynamic leader of San Diego's life sciences business community and CEO of Connect, who contributed towards innovation and strong partnerships in the region's biotech industry. The recipient of this grant gets the opportunity to work with a scientist from Thermo Fisher's Life Sciences Solutions business. The focus areas for this year's grant are peripheral cancer detection and novel applications for the Ion Torrent sequencing system. The Company informed that pre-proposal deadline is October 20, 2014. The full research reports on Thermo Fisher are available to download free of charge at:

http://www.analystsreview.com/Sep-22-2014/TMO/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review